Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Dec 18:4:356.
doi: 10.3389/fphys.2013.00356.

More than a bystander: the contributions of intrinsic skeletal muscle defects in motor neuron diseases

Affiliations
Review

More than a bystander: the contributions of intrinsic skeletal muscle defects in motor neuron diseases

Justin G Boyer et al. Front Physiol. .

Abstract

Spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), and spinal-bulbar muscular atrophy (SBMA) are devastating diseases characterized by the degeneration of motor neurons. Although the molecular causes underlying these diseases differ, recent findings have highlighted the contribution of intrinsic skeletal muscle defects in motor neuron diseases. The use of cell culture and animal models has led to the important finding that muscle defects occur prior to and independently of motor neuron degeneration in motor neuron diseases. In SMA for instance, the muscle specific requirements of the SMA disease-causing gene have been demonstrated by a series of genetic rescue experiments in SMA models. Conditional ALS mouse models expressing a muscle specific mutant SOD1 gene develop atrophy and muscle degeneration in the absence of motor neuron pathology. Treating SBMA mice by over-expressing IGF-1 in a skeletal muscle-specific manner attenuates disease severity and improves motor neuron pathology. In the present review, we provide an in depth description of muscle intrinsic defects, and discuss how they impact muscle function in these diseases. Furthermore, we discuss muscle-specific therapeutic strategies used to treat animal models of SMA, ALS, and SBMA. The study of intrinsic skeletal muscle defects is crucial for the understanding of the pathophysiology of these diseases and will open new therapeutic options for the treatment of motor neuron diseases.

Keywords: fusion defect; insulin-like growth factor 1; mouse models; myofiber degeneration; neuromuscular disease.

PubMed Disclaimer

References

    1. Aguirre T., Van Den Bosch L., Goetschalckx K., Tilkin P., Mathijs G., Cassiman J. J., et al. (1998). Increased sensitivity of fibroblasts from amyotrophic lateral sclerosis patients to oxidative stress. Ann. Neurol. 43, 452–457 10.1002/ana.410430407 - DOI - PubMed
    1. Arnold A. S., Gueye M., Guettier-Sigrist S., Courdier-Fruh I., Coupin G., Poindron P., et al. (2004). Reduced expression of nicotinic AChRs in myotubes from spinal muscular atrophy I patients. Lab. Invest. 84, 1271–1278 10.1038/labinvest.3700163 - DOI - PubMed
    1. Barber S. C., Mead R. J., Shaw P. J. (2006). Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. Biochim. Biophys. Acta 1762, 1051–1067 10.1016/j.bbadis.2006.03.008 - DOI - PubMed
    1. Beauverd M., Mitchell J. D., Wokke J. H., Borasio G. D. (2012). Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst. Rev. 11:CD002064. 10.1002/14651858.CD002064.pub3 - DOI - PMC - PubMed
    1. Biondi O., Grondard C., Lecolle S., Deforges S., Pariset C., Lopes P., et al. (2008). Exercise-induced activation of NMDA receptor promotes motor unit development and survival in a type 2 spinal muscular atrophy model mouse. J. Neurosci. 28, 953–962 10.1523/JNEUROSCI.3237-07.2008 - DOI - PMC - PubMed